Syngene Intl.
Diagnostics & Research · SYNGENE
Mid CapHealthcareHigh Growth
Peter Bains
Managing Director & CEO · Visionary
Company DNA
Innovation-Led
About
Syngene Intl. is a Mid Cap company in the Healthcare sector, listed on NSE as SYNGENE. With a market cap of ₹16K Cr and revenue of ₹4K Cr, it is currently in the High Growth phase. Known for its Innovation-Led culture and Fast-Follower approach to innovation, the company operates at a Steady-Marathon pace. R&D-focused contract research organization requiring a culture of experimentation and precision. Its strategic mandate: Continuous investment in R&D capacity and complex service delivery requires leadership focused on scientific efficiency and global client acquisition.
FAQ
What kind of company is Syngene Intl.?
Syngene Intl. is a Mid Cap Healthcare company (SYNGENE) in the High Growth phase with a market cap of ₹16K Cr. It is classified as Innovation-Led in culture.
What is Syngene Intl.'s culture and work environment like?
Syngene Intl. has a Innovation-Led culture with Fast-Follower innovation DNA and a Steady-Marathon pace of execution. Employee brand: Learning Ground. Customer relationship style: B2B-Enterprise. R&D-focused contract research organization requiring a culture of experimentation and precision.
Who leads Syngene Intl.?
Syngene Intl. is led by Peter Bains (Managing Director & CEO), a Visionary leader with 46 years of experience.
What are Syngene Intl.'s financials?
Syngene Intl. reported revenue of ₹4K Cr in FY25 with a 5-year revenue CAGR of 11.9%. Operating margin: 17.5%. Market cap: ₹16K Cr.
Culture & Strategy
CultureInnovation-Led
InnovationFast-Follower
PaceSteady-Marathon
PurposePurpose-Blended
CustomerB2B-Enterprise
EmployeeLearning Ground
BrandTechnical-Expert
LifecycleHigh Growth
R&D-focused contract research organization requiring a culture of experimentation and precision.
Mandate
Continuous investment in R&D capacity and complex service delivery requires leadership focused on scientific efficiency and global client acquisition.
Continuous investment in R&D capacity and complex service delivery requires leadership focused on scientific efficiency and global client acquisition.
Financials
Revenue FY25₹4K Cr
PAT FY25₹496 Cr
Rev CAGR 5Y11.9%
OPM17.5%
NPM14.1%
ROE10.5%
ROCE11.4%
P/E48.1
Fwd P/E36.8
P/B3.6
D/E12.3
Mkt Cap₹16K Cr
Promoter53.1%
Institutional36.3%
Similar Culture
Could You Lead Syngene Intl.?
Take the Genome Benchmark →